Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

SEATTLE-Dendreon Corporation has announced preliminary results from its analysis of its randomized, double-blind, placebo-controlled phase III study of Provenge (APC 8015) for the treatment of hormone-resistant prostate cancer. The trial of the cancer vaccine (D9901) involved 127 men with late-stage, metastatic, hormone-resistant prostate cancer, 82 of whom received Provenge, three vaccinations over a 4-week period.

SEATTLE—Dendreon Corporation has announced preliminary results from its analysis of its randomized, double-blind, placebo-controlled phase III study of Provenge (APC 8015) for the treatment of hormone-resistant prostate cancer. The trial of the cancer vaccine (D9901) involved 127 men with late-stage, metastatic, hormone-resistant prostate cancer, 82 of whom received Provenge, three vaccinations over a 4-week period.

The vaccine utilizes a recombinant form of prostatic acid phosphatase (PAP), an antigen found in 95% of prostate cancers.

The results showed that men with a Gleason score of 7 or less significantly benefited from Provenge in terms of time to disease progression.

Articles in this issue
Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Related Content
A World of Research, Care, and Science: Becoming A Radiation Oncologist

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Tim Cortese
March 12th 2025
Article

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

Darolutamide/ADT Yields Consistent Outcomes Across HSPC Age Subgroups

Ben Saylor
February 18th 2025
Article

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

First-Line Olaparib/Abiraterone Shows Clinical Benefit in BRCA+ mCRPC

First-Line Olaparib/Abiraterone Shows Clinical Benefit in BRCA+ mCRPC

Ashley Chan
February 17th 2025
Article

Olaparib plus abiraterone improved radiographic PFS and overall survival in mCRPC patients with germline or somatic BRCA mutations vs placebo plus abiraterone.